NCT06467357 2026-04-16
DESTINY-BTC01
AstraZeneca
Phase 3 Recruiting
Clinical Trials
6 trialsNCT07060807 2026-04-16
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06764875 2026-04-09
A Phase â…¢ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
AstraZeneca
Phase 3 Recruiting
NCT05950945 2026-04-08
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
Daiichi Sankyo
Phase 3 Recruiting
NCT06989112 2026-04-08
DE-01
AstraZeneca
Phase 3 Recruiting
NCT05048797 2026-04-03
A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations
AstraZeneca
Phase 3 Active not recruiting